16 Apr 2018

(258 votes)

Rigvir® for Stomach Cancer: When Applicable and What Treatment Options Exist

Claiming that a virus-based medication Rigvir® can kill stomach cancer once and for all would be taking you in the wrong direction. Though it does prolong lives and has little to no side effects as clinical trials showed.

Stemmed from the nonpathogenic (not causing a disease) natural virus, ECHO-7, Rigvir® only increases temperature a bit (up to 99.5°F/37.5°C) and may lead to tiredness.

So far, the reported side effects are moderate. That is why the Rigvir® treatment can be safely combined with chemo and radiotherapy, or used independently as a monotherapy.

Now let’s reveal the survival rate for the patients with stomach cancer, Rigvir® uses, medical reports to be sent for further evaluation of your case, and cost estimates.

Quick Facts about Rigvir® Treatment for Stomach Cancer

The discovery of virotherapy was marked by the invention of Rigvir® for melanoma  in 1950s. Later, during the clinical trials carried out in 1968-2004, the Latvian immunologists found out that the medication fights back other malignant tumors as well, including late-stage stomach cancer.

We have collected a few major facts about the Rigvir® treatment to help you make an informed decision.

Stomach cancer is highly Rigvir®-sensitive. Gastric cancer comes fourths on the list of the Rigvir®-sensitive diseases after melanomas, bladder and colorectal cancers. It means that there is a high probability of achieving positive effect after the course of Rigvir® for stomach cancer is completed.

Rigvir® impacts only the cancer cells. The Rigvir® virus is nonpathogenic and it has not been genetically modified. It only affects damaged tissues and multiplies inside cancer cells, killing them in such a way. Rigvir® does not infect healthy cells, and most importantly, it does not reproduce itself outside cancer cells as time passes.

Rigvir® extends the survival rate of the patients with stomach cancer. The survival rate for the 3rd stage stomach cancer patients after surgery is about 5 years in 24-33% of cases, compared to 47-60% for those being treated with Rigvir®.

Rigvir® can be applied to adults aged 18 or over. The medication cannot be prescribed to children under the age of 18. Besides, Rigvir® is not an option for cancer preventive measures.  

Rigvir® vials can be shipped worldwide. Despite the fact that the drug is officially registered in Latvia (2004), Armenia (2016) and Georgia (2015), its vials can be shipped to other countries including the US, the UK, Canada, Australia, and New Zealand. In 2016, its manufacturer won the Horizon 2020 grant to further make Rigvir® available to the EU pharmaceutical market.

Getting qualified for the virotherapy in 3 days. Before considering virotherapy, your case should be carefully examined by the Latvian medical board with over 30 years of experience. For that, you need to have the copies of the five medical reports to be emailed. Here is the list:

  • Biopsy (or pathology) report
  • Cytology report
  • CBC (complete blood count) + WBC (white blood cells) not older than 2 weeks
  • Blood biochemistry incl. ALT (alanine aminotransferase), creatinine, etc.
  • Radiology reports (actual images are not needed)

After your inquiry gets almost immediately confirmed, you will get a response from the medical staff within three days at latest including further recommendations on the treatment if virotherapy is a good fit for you. Kindly note that the list of files to submit stays the same whether you are looking for Rigvir for kidney cancer or virotherapy for colon cancer.

If you feel like there are still some questions unanswered, you are welcome to get in touch with us. Just click the red button below to address your inquiry and we will respond within 24 hours or sooner.